CELU earnings analysis
What we found in CELU's 10-K: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Celularity Inc. faced significant challenges in 2025, culminating in a net loss of $91.7 million and a troubling cash position of $6.2 million. The company reported a steep decline in product sales, notably a 62.7% drop to $13.2 million, as uncertainty surrounding insurance reimbursements affected purchasing behavior. As a result, operational inefficiencies and a drastic capital deficit of $68.4 million raised substantial doubts about its ability to continue as a going concern. Various financing activities have aimed to secure additional capital, but the timing and feasibility remain uncertain.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Transition Focus on Cell Therapy
- The Company is aiming to streamline operations towards a cell therapy pipeline, highlighted by restructuring efforts in 2026.
- Debt Reduction Efforts
- The sale of certain biomaterials assets to NexGel for $13.3 million included a cash payment of $8.3 million, significantly aiding cash flows.
- Improvement in BioBanking Revenue
- BioBanking services grew by 5.7%, contributing $5.4 million to overall revenue, showcasing some operational resilience.
- Dividend Cuts and Cost Reductions
- A decline in executive compensation and non-essential expenditures has been initiated to conserve cash and resources.
- Warrant and Convertible Note Issuances
- Issuance of Series A Preferred Stock with warrants aimed at raising capital totalled $2,000, providing some liquidity assistance.
- Strategic Partnerships Pursued
- Plans for strategic sales partnerships are expected to enhance liquidity and operational support.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Liquidity Crisis
- With only $6.2 million in cash as of Dec 31, 2025, and existing debts, substantial concerns about the ability to continue operations exist.
- Operational Deficits
- Significant operational losses totaling $91.7 million were reported for the year, alongside a working capital deficit of $68.4 million.
- Regulatory Approval Risks
- The company faces challenges in obtaining timely regulatory approvals for its pipelines, delaying commercialization and incurring additional costs.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-3.59
- Gross margin
- 31.75%
- Operating margin
- -230.98%
- Segment
- Cell Therapy
- Segment
- BioBanking
- Segment
- Degenerative Disease
What they said about what is next.
Guidance deferred to earnings press release / call.
The filing reads worse than the one before it.
What came before.
- 10-Q · August 29, 2025
- Celularity reported Q2 revenue of $5.736M, down sharply from $12.111M a year ago, driven by a collapse in product sales. Gross margin compressed to 8.6% (from 82.5% a year ago) and operating loss and net loss widened,…
- 10-K · May 8, 2025
- Celularity positions itself as a regenerative and cellular medicines company focused on placental-derived biomaterials and off‑the‑shelf allogeneic cell therapies, leveraging its Celularity IMPACT integrated…
- 10-Q · December 6, 2024
- Q3 (three months ended September 30, 2024) revenue was $9.296M, up materially year-over-year from $3.786M, driven by license/royalty and product sales. Gross margin improved to ~58.3% and loss from operations narrowed…
- 10-Q · November 7, 2024
- Q2 (period ended June 30, 2024) showed a sharp revenue rebound to $12.111M driven by product sales, with very high gross margin (82.5%) but the company remains unprofitable with an operating loss of $10.175M and net…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CELU makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever